The discovery in 2001 that de novo mutations in SCN1A cause Dravet syndrome [10], one of the best-studied EEs, set the stage for the de novo paradigm for this class of disorders. This evidence concerns the gene SCN1A and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.